文献速递类风湿关节炎

安全数据发布后类风湿关节炎先进治疗启动与停用患者特征的变化

Changes in Characteristics of Patients Initiating and Discontinuing Advanced Therapies for Rheumatoid Arthritis Following the Release of Safety Data.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2024-01-12

该队列研究纳入2019年4月至2022年9月的美国退伍军人类风湿关节炎患者,比较2021年1月前后两个664天期间启动和停用先进治疗的患者特征。结果显示,托法替布启动者平均年龄及心血管合并症比例下降,且托法替布停药可能性高于TNFi。

要点

  • 2021年1月后启动托法替布的患者平均年龄和心血管合并症比例较之前下降。
  • 托法替布停药可能性高于TNFi,风险比1.18(95%CI 1.10-1.26,P<0.001)。
  • 有心血管合并症时托法替布停药率更高(P<0.05)。

核心结论

  • 近期安全数据显著影响了先进治疗的处方实践,老年及高心血管风险患者中JAKi启动减少、停用增加。

研究设计与样本

  • 队列研究,评估2019年4月至2022年9月期间的美国退伍军人类风湿关节炎患者,分为2021年1月前后两个664天期间。
  • 纳入患者至少有1个类风湿关节炎诊断代码并启动TNFi、非TNFi生物制剂或JAKi。
  • 使用回归模型检验交互作用,以确定托法替布接受者特征变化是否与其他治疗不同。
  • 使用Cox模型评估与治疗停用相关的因素,调整年龄、性别和治疗持续时间,并评估效应修饰。

主要发现

  • 2021年1月前启动托法替布者n=2,111,之后启动者n=1,664;平均年龄从64.1岁降至63.0岁,心血管合并症比例下降(所有P<0.01)。
  • 这些变化与启动TNFi或非TNFi生物制剂的患者相比有显著差异。
  • 在活跃的先进治疗接受者中,托法替布停药可能性高于TNFi(风险比1.18,95%CI 1.10-1.26,P<0.001)。
  • 有心血管合并症时,托法替布停药率更高(P<0.05)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The objective of this study was to determine the impact of emerging safety data on practice patterns by describing the characteristics of patients initiating and discontinuing advanced therapies for rheumatoid arthritis (RA) before and after January 2021. METHODS: This cohort study evaluated US veterans with RA between April 2019 and September 2022. This period was divided into two 664-day periods before and after January 2021. Eligible patients had ≥1 diagnosis code for RA and initiated a tumor necrosis factor inhibitor (TNFi), non-TNFi biologic, or JAK inhibitor (JAKi). We tested for interaction within regression models to determine whether changes in patient characteristics for tofacitinib recipients were different from changes observed for other therapies. We also evaluated factors associated with therapy discontinuation in Cox models adjusted for age, sex, and duration on therapy, including assessment for effect modification. RESULTS: When comparing patients with RA initiating tofacitinib before (n = 2,111) with those initiating tofacitinib after (n = 1,664) January 2021, there was a decrease in mean age (64.1 vs 63.0 years) and in the proportion with cardiovascular comorbidities (all P < 0.01). These changes were significantly different from those observed for patients initiating TNFi or non-TNFi biologics. Among active advanced therapy recipients, the likelihood of discontinuation was higher for tofacitinib than TNFi (hazard ratio 1.18, 95% confidence interval 1.10-1.26, P < 0.001). The higher rate of tofacitinib discontinuation was more pronounced in the presence of cardiovascular comorbidities (P < 0.05). CONCLUSION: Recent safety data significantly affected prescribing practices for advanced therapies, with a reduction in JAKi initiation and an increase in JAKi discontinuation among older patients and those at high cardiovascular risk.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Song S, England BR, Sauer B, et al. Changes in Characteristics of Patients Initiating and Discontinuing Advanced Therapies for Rheumatoid Arthritis Following the Release of Safety Data. Arthritis Care Res (Hoboken). 2024. PMID: 37909392. doi:10.1002/acr.25268

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。